Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01413542 · ClinicalTrials.gov registry record · NA
Pharmacogenetics of Ace Inhibitor-Associated Angioedema
A NA study, sponsored by Vanderbilt University.
- Completed
- Registry status
- NA
- Development phase
- 44
- Enrollment target
NCT01413542: Completed NA study, sponsored by Vanderbilt University.
NCT01413542 is a NA study that has completed, run by Vanderbilt University. The registered enrollment target is 44 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (97% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01413542, a NA study, has completed, sponsored by Vanderbilt University.
- COMPLETED
- Registry status
- NA
- Development phase
- 44 participants
- Enrollment target
Study Summary
The investigators would like to find out if sitagliptin (dipeptidyl peptidase-4 or DPP4 inhibition), a drug to treat diabetes, affects blood vessel relaxation in healthy people receiving enalapril (angiotensin converting enzyme or ACE inhibition), a blood pressure medicine. Understanding how these drugs interact in healthy people will help us learn their potential effects in people who have diabetes.
Primary Outcome
Forearm blood flow (FBF) was measured by strain gauge plethysmography at the completion of each dose of intra-arterial peptide. A dose response curve was therefore constructed for each vasoactive peptide substrate. The effect of sitagliptin (DPP4 inhibition) vs. placebo and enalaprilat (ACE inhibition) vs. vehicle on the forearm blood flow response to each peptide could then be determined.
Interventions
- DRUG Sitagliptin (DPP4 inhibitor)
- DRUG Substance P,
- DRUG bradykinin
- DRUG enalaprilat (ACE inhibitor)
- DRUG Glucagon-like peptide 1
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 44 participants |
| Start Date | 2011-11 |
| Est. Completion | 2014-07 |
| Phase | NA |
What the finished NCT01413542 record still lists
NCT01413542 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 44 participants, a relatively small participant target, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (97% lower).
The record links to 0 conditions, and to 5 interventions - of which Sitagliptin (DPP4 inhibitor) is the first listed.
NCT01413542 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01413542 about?
NCT01413542 is a clinical study titled "Pharmacogenetics of Ace Inhibitor-Associated Angioedema". The investigators would like to find out if sitagliptin (dipeptidyl peptidase-4 or DPP4 inhibition), a drug to treat diabetes, affects blood vessel relaxation in healthy people receiving enalapril (angiotensin converting enzyme or ACE inhibition), a blood pressure medicine. Understanding how these d...
What is the current status of trial NCT01413542?
This trial is currently completed. It is a NA study. The enrollment target is 44 participants. The study started on 2011-11. Estimated completion is 2014-07.
What interventions are being tested in trial NCT01413542?
The interventions under investigation include: Sitagliptin (DPP4 inhibitor) (DRUG), Substance P, (DRUG), bradykinin (DRUG), enalaprilat (ACE inhibitor) (DRUG), Glucagon-like peptide 1 (DRUG).
Who is sponsoring clinical trial NCT01413542?
This trial is sponsored by Vanderbilt University, which has 430 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT01413542's enrollment target sits among peer trials
44 1423rd of 2000 higher than 566 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02323945 · 44 participants · NA
Effects of Breathing Mild Bouts of Low Oxygen on Limb Mobility After Spinal Injury
- NCT03093909 · 44 participants · Phase 1
Study of Aerosol Gemcitabine in Patients With Solid Tumors and Pulmonary Metastases
- NCT03104491 · 44 participants · Phase 1
Inotuzumab Ozogamicin Post-Transplant For Acute Lymphocytic Leukemia
- NCT03781765 · 44 participants · Phase 4
Stimulant vs. Non-stimulant Treatments and Reward Processing in Drug-naive Youth at SUD Risk
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia